Cordis Pipeline Aimed At Keeping Double-Digit Share Of U.S. Stent Market
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's Cordis unit is hoping that the introduction of new coronary stent families combined with a series of planned improvements to existing stent offerings will allow the company to maintain a double-digit share of the U.S. market in the face of burgeoning competition.